• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders

ORGS

Orgenesis Inc.

$0.59

+0.10 (+19.19%)

Market Metrics

Open

$0.59

Prev. Close

$0.49

Day Low

$0.59

Day High

$0.59

52W Low

$0.02

52W High

$5.89

Market Cap

$0.00B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

61.9%

Avg Negative

4.3%

Avg Neutral

33.7%

News Feed

Orgenesis says Ranpirnase advancing towards multiple indications after FDA consultation and presentation of positive results

Proactive Investors·7/6/2021·↑ positive

Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator

Proactive Investors·6/10/2021·↑ positive

Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing

Seeking Alpha·5/17/2021·↓ negative

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/10/2021·↓ negative

ORGS Stock: Over 10% Increase Intraday Explanation

Pulse2·5/7/2021·↑ positive

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy

Proactive Investors·5/7/2021·↑ positive

ORGS Stock: 14.06% Increase Pre-Market (From $4.48 To $5.11) Explanation

Pulse2·5/6/2021·↑ positive

Orgenesis reaches milestone with US FDA approval of Tissue Genesis Icellator2 pilot trial

Proactive Investors·5/6/2021·↑ positive

Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre

Proactive Investors·3/29/2021·↑ positive

Orgenesis to collaboration with Bambino Gesù Children's Hospital in Rome on new therapy centre

Proactive Investors·3/29/2021·↑ positive